The long-term efficacy and tolerability of donepezil in patients with vascular dementia

International Journal of Geriatric Psychiatry

Volumn 25, Issue 3, 2010, Pages 305-313

  Wilkinson, David ^a   Róman, Gustavo ^b   Salloway, Stephen ^c   Hecker, Jane ^d   Boundy, Karyn ^e   Kumar, Dinesh ^f   Posner, Holly ^g   Schindler, Rachel ^g  

^a MOORGREEN HOSPITAL   (United Kingdom)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c BUTLER HOSPITAL   (United States)

^d REPATRIATION GENERAL HOSPITAL   (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f EISAI INC   (United States)

^g PFIZER INC   (United States)

Author keywords

Cholinesterase inhibitor; Donepezil; Efficacy; Long term trial; Safety; Tolerability; Vascular dementia

Indexed keywords

ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; DONEPEZIL; HYPNOTIC AGENT; TRANQUILIZER; VITAMIN;

ACCIDENTAL INJURY; AGED; ALZHEIMER DISEASE; AMBULATORY CARE; ARTICLE; ASTHENIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NAUSEA; NEUROLOGIC DISEASE; OPEN STUDY; PAIN; PARALLEL DESIGN; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DEMENTIA, VASCULAR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES;

EID: 76649086048     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2340     Document Type: Article

References (15)

1. Andersen CK, Wittrup-Jensen KU, Lolk A, Andersen K, Kragh-Sorensen P. 2004. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2: 52.
2. Black S, Román GC, Geldmacher DS, et al. Donepezil 307 Vascular Dementia Study Group. 2003. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34: 2323-2330.
3. Cannata AP, Alberoni M, Franceschi M, Mariani C. 2002. Frontal impairment in subcortical ischemic vascular dementia in comparison to Alzheimer's disease. Dement Geriatr Cogn Disord 13: 101-111.
4. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. 2001a. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58: 427-433.
5. Doody RS, Stevens JC, Beck C, et al. 2001b. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1154-1166.
6. Dubois MF, Hebert R. 2001. The incidence of vascular dementia in Canada: a comparison with Europe and East Asia. Neuroepidemiology 20: 179-187.
7. Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. 1995. The consortium to establish a registry for Alzheimer's disease (CERAD). part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology 45: 1451-1455.
8. Kavirajan H, Schneider LS. 2007. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta - analysis of randomised controlled trials. Lancet Neurol 6: 782-792.
9. Kittner B, De Deyn PP, Erkinjuntti T. 2000. Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials. Ann NY Acad Sci 903: 535-541.
10. Pratt RD. 2002. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J Neurol Sci 203-204: 57-65.
11. Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. 2005. Donepezil in vascular dementia: combined analysis of two largescale clinical trials. Dement Geriatr Cogn Disord 20: 338-344.
12. Roman G, Black S, Royall DR, et al. 2006. Efficacy and safety of donepezil in vascular dementia: results from the largest double-blind trial in vascular dementia patients. Eur Neuropsychopharm 16 (Suppl 4): S481-S482.
13. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. 1996. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 103: 1211-1220.
14. Wilkinson D, Doody R, Helme R, et al. Donepezil 308 Study Group. 2003. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61: 479-486.
15. Wlodarczyk JH, Brodaty H, Hawthorne G. 2004. The relationship between quality of life, mini-mental state examination, and the instrumental activities of daily living in patients with Alzheimer's disease. Arch Gerontol Geriatr 39: 25-33.